Core Insights - The company experienced a solid start to the year with high single-digit growth in its three largest end markets, resulting in a Q1 core growth of 4.4% [2] - The growth was negatively impacted by winter weather in the U.S. during the last week of the quarter, but adjusted figures would have shown better performance [2] - The three largest markets driving growth are Pharma, Clinical & Diagnostics, and CAM, all benefiting from favorable secular tailwinds [3] Market Analysis - In the Pharma sector, key drivers include MFN Clarity, the ramp-up of GLP-1s, the rise of siRNA modalities, and anticipated reshoring by 2027 [3] - The Clinical & Diagnostics market is supported by an aging population and an increasing incidence of cancer, which drives higher test volumes [3]